A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Breast or Gastrointestinal Cancer Patients
18 Years
N/A
Both
Breast Cancer, Fatigue, Gastrointestinal Cancer
Trial Information
A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Breast or Gastrointestinal Cancer Patients
OROS Methylphenidate HCl is a mild central nervous system stimulant. Cytokines are a type
of protein found in blood. Medical researchers here at M. D. Anderson are working to see if
they are related to, or can tell us something about, fatigue and its symptoms.
This study will be divided into two, 14-day periods. During one of the 14-day periods, you
will be given the study drug. During the other period, you will be given a placebo. A
placebo is a sugar tablet that looks just like the study drug tablet.
You will be randomly picked (as in the toss of a coin) to be in one of two treatment groups.
In one group you will receive the study drug first and the placebo second. In the other
group you receive the placebo first and the study drug second. The chance of being in either
treatment group is about equal. Neither you nor the research staff will know which
treatment order you are assigned to.
Before treatment starts, you will fill out questionnaires about your level of fatigue,
distress, symptoms, and general health. It should take about 5 minutes to complete the
questionnaires. You will have a medical history, physical exam (with pulse, temperature,
blood pressure), and blood work done. At the start of the study a test of the heart called
an EKG will be done. At the start of the study, and after you finish the study, you will
complete additional questionnaires that measure mood, fatigue, sleep, and appetite. It
should take about 15 minutes to complete the questionnaires. You will also complete a
series of tests for memory, visual-motor, and thinking functions. These tests should take
about 30 minutes to complete. (This evaluation may take place on or before Day 1 of the
study.)
On Day 1, a set of study medications and a diary will be given to you. For the first
fourteen days of the study, you will take the assigned study medication (either drug or
placebo). Everyday you will fill out the diary, noting the time you took the study
medication and answering two questions about your fatigue.
On Day 7, study personnel will see you in the clinic or Ambulatory Treatment Center. The
delegated research personnel will take your blood pressure and pulse and ask you about any
symptoms or complaints you may have had or any medications you may have taken.
On Day 14, study personnel will see you in the clinic or the Ambulatory Treatment Center
where blood pressure and pulse will be measured. Unused study medication will be returned
and your diary will be reviewed with the delegated research personnel. You will complete
questionnaires asking about fatigue, sleep, depression, and symptoms. It should take about
15 minutes to complete them. You will also complete a series of tests for memory,
visual-motor, and thinking functions. The tests should take about 30 minutes to complete. A
blood draw will be done to look for changes in hemoglobin and for cytokine analysis.
A new set of study medications and a diary will be given to you. You will follow the same
instructions as the first time period. You will take the assigned study medication every
morning and fill out the diary, noting the time you took the study medication and answering
two questions about your fatigue.
On Day 21, the same activities as Day 7 will occur.
If you are not scheduled to come to M. D. Anderson on Day 7 and Day 21, you will take 2
separate blood pressure measurements 5 minutes apart for each day and report results within
24 hours to the research staff. If you choose to take your blood pressure measurements at
home, you need to bring your monitor at study enrollment to have measurements double-checked
by research staff.
On Day 28, the study will end. The same activities as Day 14 will occur. In addition, you
will have a physical exam.
You will be asked if you prefer the first (first 2 weeks of study) or second (second 2 weeks
of study) treatment phase. If you want to continue taking the OROS Methylphenidate you will
be allowed to do so off-study as long as there are no medical reasons not to.
This is an investigational study. The study drug has been approved for attention-deficit
hyperactivity disorder but is investigational as a treatment for cancer related fatigue.
The study medication and physical exams will cost you nothing. You will be reimbursed with a
fixed amount of money for each scheduled study visit. The payment will be in the form of a
gift card for parking expenses and a gift card for gas expenses. The study doctor or study
staff can tell you more about when you will be able to receive reimbursement. A total of 50
patients will take part in this study. All will be enrolled at The University of Texas (UT)
MD Anderson.
Inclusion Criteria:
1. Patient diagnosed with breast, gastrointestinal, lymphoma, myeloma or lung cancer
undergoing chemotherapy or hormonal treatment
2. Patient is > or = 18 years of age
3. Patient has Brief Fatigue Inventory "fatigue worst" score of > or = 4 at baseline
4. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of < or =
2 at baseline
5. Patient has a life expectancy > or = 6 months from the start of the study
6. Patient is using acceptable birth control methods. Female participants (if of child
bearing potential and sexually active) and male participants (if sexually active with
a partner of child-bearing potential) must use medically acceptable methods of birth
control. Medically acceptable methods of contraception include abstinence, birth
control pills, diaphragm with spermicide, condom with foam or spermicide, vaginal
spermicidal suppository or surgical sterilization
7. Patient must speak and understand English
8. Patient has provided written informed consent to participate in the study prior to
enrollment to the study
Exclusion Criteria:
1. History of hypersensitivity reaction to methylphenidate
2. History of or current seizure disorder, glaucoma, major psychiatric diagnosis,
narcolepsy, Tourette's syndrome, tension or agitation
3. History of clinically significant cardiac disease.
4. Uncontrolled hypertension: has not been on a stable treatment dose for the past
month, or has a systolic pressure consistently (defined as 3 consecutive blood
pressure readings within the last 30 days) greater than 150 mm Hg or diastolic
pressure consistently greater than 85 mm Hg
5. History of fibromyalgia
6. Use of alcohol while participating in the study
7. Current use of illicit drugs or history of alcohol or drug abuse and/or abuse
potential (see protocol for criteria)
8. Moderate to severe depression (> or = 20 on Beck Depression Index II)
9. If taking antidepressants, no changes in dose and/or no start of new course of
treatment in the last 30 days
10. Currently taking psychostimulants (including appetite suppressants), monoamine
oxidase (MAO) inhibitors, anticoagulant or anticonvulsant therapy
11. Current use of corticosteroids, medications, or stimulants (i.e., vivarin) used to
improve fatigue symptoms
12. Use of an investigational medication within the past month
13. Current use of the following herbals or supplements for fatigue relief (DHEA, SAME,
ginkgo, ginseng, St. John's Wort (including DHEA, SAME, ginkgo, ginseng, St. John's
Wort, metabolite, effedrin, basil, citronella, fennel, horseradish roots, lavender
flowers, lemon verbena, marjoram, mint, nettle, pine needles, rosemary, sage, savory,
thyme, bay, cayenne pepper, cinnamon, eucalyptus, hyssop, myrrh, oregano, peppermint,
ginseng, green, black or Chinese tea, ephedra (aka - ma-huang), popotillo, and Mormon
tea)
14. Any coexisting medical condition or are taking any concomitant medication that is
likely to interfere with the safe administration of methylphenidate
15. Patients who start epoetin within 30 days prior to enrollment
16. Patients who start taking epoetin during the first week of the study
17. Hemoglobin < 8.0 gm/dl
18. Patients with a thyroid-stimulating hormone (TSH) value > or = 1.5 times the upper
limit of normal (ULN)
19. Albumin value 50% lower than the lower limit of normal
20. Evidence of hepatic impairment [total bilirubin > or = 2.5 times ULN (normal range of
0 - 1.0 mg/dl, serum glutamate pyruvate transaminase (SGPT) > or = 2.5 times ULN)]
21. Evidence of renal impairment (serum creatinine > 2.5 times ULN, normal range of 0.8 -
1.5 mg/dl)
22. A severe narrowing (pathological or iatrogenic), obstruction of the gastrointestinal
tract, or gastrointestinal malabsorption
23. If taking anxiolytics, and/or hypnotics, no changes in dose and/or no start of new
course of treatment in the last 30 days
24. Patients with nausea, vomiting, or diarrhea of Common Toxicity Criteria for Adverse
Effects (CTCAE) grade III or higher
25. If taking anticonvulsants for sensory neuropathy (Gabapentin or Pregabalin), no
changes in dose and/or no start of new course of treatment in the last 30 days
26. History of severe headaches within 30 days prior to enrollment
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Outcome Measure:
Mean Difference Between Post-Methylphenidate and Post-Placebo Measurement
Outcome Description:
The primary endpoint is the "fatigue worst" score (range: 0 - 10) on the Brief Fatigue Inventory (BFI) at the end of two-week treatment (either Methylphenidate or placebo). "Worst fatigue" is defined as participants' rating of worst fatigue on a scale of 0 (no fatigue) to 10 (as bad as can imagine). Since each participant is expected to receive both 2-week of Methylphenidate or 2-week placebo at different times, they serve as their own control. The outcome is the difference in "fatigue worst" score between post-Methylphenidate measurement and post-Placebo measurement.
Outcome Time Frame:
At end of two 2-week treatment cycles (4 weeks total)
Safety Issue:
No
Principal Investigator
Carmen Escalante, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
M.D. Anderson Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
ID00-372
NCT ID:
NCT00516269
Start Date:
August 2004
Completion Date:
November 2013
Related Keywords:
- Breast Cancer
- Fatigue
- Gastrointestinal Cancer
- Breast Cancer
- Gastrointestinal Cancer
- GI Cancer
- Fatigue
- OROS Methylphenidate HCl
- Methylphenidate
- Methylphenidate Hydrochloride
- Concerta
- Ritalin
- Placebo
- Breast Neoplasms
- Fatigue
- Gastrointestinal Neoplasms
Name | Location |
|---|---|
| UT MD Anderson Cancer Center | Houston, Texas 77030 |
